Denali Free Cash Flow vs Investments Analysis
DNLI Stock | USD 18.90 0.31 1.61% |
Denali Therapeutics financial indicator trend analysis is much more than just examining Denali Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Denali Therapeutics is a good investment. Please check the relationship between Denali Therapeutics Free Cash Flow and its Investments accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.
Free Cash Flow vs Investments
Free Cash Flow vs Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Denali Therapeutics Free Cash Flow account and Investments. At this time, the significance of the direction appears to have pay attention.
The correlation between Denali Therapeutics' Free Cash Flow and Investments is -0.89. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Investments in the same time period over historical financial statements of Denali Therapeutics, assuming nothing else is changed. The correlation between historical values of Denali Therapeutics' Free Cash Flow and Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Denali Therapeutics are associated (or correlated) with its Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Investments has no effect on the direction of Free Cash Flow i.e., Denali Therapeutics' Free Cash Flow and Investments go up and down completely randomly.
Correlation Coefficient | -0.89 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Investments
Securities or assets acquired for generating income or appreciating in value, not used in daily operations.Most indicators from Denali Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Denali Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.The current Selling General Administrative is estimated to decrease to about 54.3 M. The current Tax Provision is estimated to decrease to -6,300
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 4.6M | 14.8M | 51.5M | 54.1M | Net Interest Income | 4.6M | 14.8M | 45.0M | 47.3M |
Denali Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Denali Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Denali Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 553.2M | 1.6B | 1.4B | 1.5B | 1.2B | 932.8M | |
Other Current Liab | 20.4M | 42.5M | 47.7M | 63.8M | 61.2M | 31.3M | |
Total Current Liabilities | 45.3M | 71.7M | 378.2M | 363.9M | 78.0M | 121.8M | |
Total Stockholder Equity | 394.9M | 1.2B | 962.3M | 1.0B | 1.0B | 712.9M | |
Other Liab | 44.1M | 317.9M | 5.1M | 858K | 986.7K | 937.4K | |
Net Tangible Assets | 394.9M | 1.2B | 962.3M | 1.0B | 1.2B | 612.3M | |
Property Plant And Equipment Net | 80.7M | 73.5M | 69.6M | 74.5M | 71.6M | 52.4M | |
Net Debt | (10.6M) | (443.0M) | (234.9M) | (157.7M) | (74.9M) | (78.6M) | |
Retained Earnings | (425.6M) | (354.4M) | (645.0M) | (971.0M) | (1.1B) | (1.1B) | |
Accounts Payable | 2.6M | 1.1M | 4.8M | 2.8M | 9.5M | 10.0M | |
Cash | 79.4M | 507.1M | 293.5M | 218.0M | 127.1M | 194.5M | |
Non Current Assets Total | 123.2M | 108.6M | 506.9M | 87.9M | 89.8M | 154.9M | |
Non Currrent Assets Other | 2.7M | 2.5M | 11.9M | 11.9M | 16.5M | 17.4M | |
Other Assets | 2.7M | 2.5M | 11.9M | 13.4M | 1.0 | 0.95 | |
Cash And Short Term Investments | 415.4M | 1.5B | 865.4M | 1.3B | 1.0B | 757.9M | |
Common Stock Shares Outstanding | 95.6M | 112.7M | 121.5M | 125.5M | 137.4M | 86.7M | |
Liabilities And Stockholders Equity | 553.2M | 1.6B | 1.4B | 1.5B | 1.2B | 932.8M | |
Non Current Liabilities Total | 113.0M | 382.1M | 63.6M | 53.9M | 45.0M | 42.7M | |
Capital Surpluse | 774.2M | 818.8M | 1.5B | 1.6B | 1.8B | 1.9B | |
Other Current Assets | 14.7M | 20.3M | 30.6M | 36.1M | 26.9M | 18.9M | |
Other Stockholder Equity | 818.8M | 1.5B | 1.6B | 2.0B | 2.1B | 1.1B | |
Total Liab | 158.3M | 453.7M | 441.9M | 417.8M | 123.0M | 220.0M | |
Property Plant And Equipment Gross | 80.7M | 73.5M | 69.6M | 74.5M | 117.6M | 123.5M | |
Total Current Assets | 430.0M | 1.5B | 897.2M | 1.4B | 1.1B | 778.0M | |
Accumulated Other Comprehensive Income | 350K | (245K) | (2.5M) | (6.9M) | 643K | 675.2K | |
Common Stock | 1.3M | 1.5M | 1.5M | 1.7M | 1.7M | 1.6M | |
Property Plant Equipment | 80.7M | 40.8M | 69.6M | 74.5M | 85.7M | 44.6M | |
Short Term Investments | 335.9M | 962.6M | 571.9M | 1.1B | 907.4M | 633.8M | |
Long Term Investments | 61.3M | 147.9M | 39.9M | 32.7M | 425.4M | 0.0 | |
Non Current Liabilities Other | 467K | 471K | 379K | 382.1M | 435.9K | 414.1K | |
Net Invested Capital | 394.9M | 1.2B | 962.3M | 1.0B | 1.0B | 879.0M | |
Net Working Capital | 384.7M | 1.4B | 519.0M | 1.0B | 986.2M | 811.7M | |
Current Deferred Revenue | 18.7M | 23.5M | 320.3M | 290.1M | 333.6M | 350.2M | |
Capital Stock | 1.3M | 1.5M | 1.5M | 1.7M | 1.7M | 1.7M | |
Short Term Debt | 3.7M | 4.7M | 5.5M | 7.3M | 7.3M | 6.3M |
Currently Active Assets on Macroaxis
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 2.101 | Quarterly Revenue Growth (1.00) | Return On Assets (0.09) | Return On Equity (0.11) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.